Quick Answer
BioXcel Therapeutics, Inc. reported Total Assets of $44.92 million for the year ending 2025.
- BioXcel Therapeutics, Inc. showed an increase of +17.2% in Total Assets from 2024 to 2025.
- This data is from BioXcel Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $56.32 million | Q2 2018: $51.21 million | Q3 2018: $47.87 million | Q1 2019: $40.33 million | Q2 2019: $34.28 million | Q3 2019: $43.70 million | Q1 2020: $85.81 million | Q2 2020: $70.46 million | Q3 2020: $238.75 million | Q1 2021: $200.39 million | Q2 2021: $281.11 million | Q3 2021: $261.33 million | Q1 2022: $211.05 million | Q2 2022: $248.24 million | Q3 2022: $244.82 million | Q1 2023: $180.10 million | Q2 2023: $140.10 million | Q3 2023: $100.45 million | Q1 2024: $82.32 million | Q2 2024: $65.44 million | Q3 2024: $48.89 million | Q1 2025: $38.57 million | Q2 2025: $25.79 million | Q3 2025: $44.79 million.
- Over the full 9 years of available data (2017 to 2025), BioXcel Therapeutics, Inc.'s Total Assets has grown by 3,214.8%.
- Historical annual values: Fiscal year 2025: $44.92 million | Fiscal year 2024: $38.34 million | Fiscal year 2023: $73.70 million | Fiscal year 2022: $205.85 million | Fiscal year 2021: $239.44 million | Fiscal year 2020: $219.94 million | Fiscal year 2019: $36.39 million | Fiscal year 2018: $43.55 million | Fiscal year 2017: $1.36 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: